SCHEMBL24216545

SCHEMBL24216545

CC(C)(F)C(=O)Nc1cccc(-c2cn(Cc3ccc(-c4nnc(C(F)F)o4)cc3F)nn2)c1

nearest known ligand 0.44

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.44
▸ UCHL5 Q9Y5K5 1/20 0.42
▸ HDAC1 Q13547 11/20 0.41
▸ HDAC6 Q9UBN7 5/20 0.41
▸ HDAC3 O15379 3/20 0.41
▸ HDAC2 Q92769 2/20 0.41
▸ HDAC10 Q969S8 2/20 0.41
▸ HDAC8 Q9BY41 2/20 0.41
▸ KDR P35968 2/20 0.40
▸ TEK Q02763 1/20 0.40
▸ AR P10275 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25993017 0.94 KDM4E (0.52) KDM4EUCHL5HDAC1HDAC6HDAC3
SCHEMBL25352241 0.94 HDAC1 (0.42) KDM4EUCHL5HDAC1HDAC6HDAC3
SCHEMBL25350635 0.92 HDAC6 (0.44) UCHL5HDAC1HDAC6HDAC3HDAC2
SCHEMBL25993048 0.92 KDM4E (0.42) KDM4EUCHL5HDAC1HDAC6HDAC3
SCHEMBL24215838 0.90 UCHL5 (0.49) UCHL5HDAC1HDAC6HDAC3HDAC2
SCHEMBL30409726 0.90 UCHL5 (0.49) UCHL5HDAC1HDAC6HDAC3HDAC2
SCHEMBL25350937 0.90 HDAC6 (0.44) UCHL5HDAC1HDAC6HDAC3HDAC2
SCHEMBL25992763 0.89 HDAC1 (0.42) UCHL5HDAC1HDAC6HDAC3HDAC2
SCHEMBL30409499 0.89 HDAC6 (0.50) KDM4EUCHL5HDAC1HDAC6HDAC3
SCHEMBL24215759 0.89 HDAC6 (0.50) KDM4EUCHL5HDAC1HDAC6HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257372-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-17 — — US disclosed
US-20230257372-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-17 — — US disclosed
WO-2022013728-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2022-01-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257372-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HDAC6, HDAC1, HDAC3 KDM4E 544/4885UCHL5 1041/4885HDAC1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback